473 results about "Angor pectoris" patented technology

Compounds of the formula

wherein R₁, R₂, R₃, R₄, X and Y are as defined, which have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis, and the like; allergic diseases such as asthma, or disorders of male or female genital function and the like.

The invention discloses a preparation method of Radix Puerariae wine. The preparation method comprises the following steps: collecting fresh Radix Puerariae, cleaning, cutting into pieces, adding water, and performing homogenate to obtain a Radix Puerariae homogenate liquid; sterilizing the Radix Puerariae homogenate liquid at 70-110 DEG C for 5-120 minutes, cooling to 50-65 DEG C, and regulatingthe pH value to 5-7 to obtain a sterilized solution; adding amylase into the sterilized solution until the mass percentage of the amylase is 0.01-5, performing enzymolysis at 50-90 DEG C for 0.5-24 hours, adding glucoamylase until the mass percentage of the glucoamylase is 0.01-5, and performing enzymolysis at 50-70 DEG C for 4-12 hours; then increasing the temperature to 70-110 DEG C, holding the temperature for 20-150 minutes, and cooling to 20-60 DEG C to obtain an enzymolysis solution; and finally adding saccharomyces cerevisiae into the enzymolysis solution until the mass percentage of the saccharomyces cerevisiae is 0.01-0.05, fermenting at 24-40 DEG C for 5-10 days, and filtering to obtain the Radix Puerariae wine. The preparation method is simple; and the prepared Radix Puerariae wine is high in Puerarin content and has an alcohol degree of 15-35, and can be applied to adjuvant therapy for diseases such as hypertension, angina pectoris, coronary heart disease, hyperlipidemia and the like.

The invention relates to a fructus crataegi flaked candy and a preparation method of the fructus crataegi flaked candy. The flaked candy comprises, by weight, 1-40 pars of fructus crataegi powder, 5-30 parts of microcrystalline cellulose, 5-60 parts of sorbit, 5-30 parts of maltodextrin, 0.1-4 parts of lubricants and appropriate adhesion agents. Smashing, 80-mesh screening and even mixing are performed on the fructus crataegi powder and all the auxiliary materials, and then damp mass preparing, granulation, drying, granule arranging and flaking are performed to obtain the fructus crataegi candy. The fructus crataegi flaked candy has the functions of strengthening the spleen and stomach and aiding digestion, and has a certain therapeutic effect on high blood pressure, coronary disease, angor pectoris, hyperlipemia, stomachache, diarrhea and other diseases.

An ethylester of fatty acid containing high-content and-purity DHA and high-purity EPA, especially EPA-E and DHA-E in weight ratio of 1: (1.01-38), a medicine prepared from it for preventing and treating hyperlipemia, angina pectoris and cerebral infarction, and its preparing process are disclosed.

The invention discloses an application of sichuan lovage rhizome oil by supercritical CO2 extraction method in pharmacy, which can be used for treating vascular nerve cephalalgia, cerebral thrombus, cerebrovascular angiosclerosis, coronary heart diseases, angina pectoris, hypertension, or asomnia, or common cold, or women's dysmenorrheal.

The invention discloses a Chinese medicinal composition for treating cardiovascular diseases, which is prepared mainly from root of red rooted saliva, haw thorn, Chinese angelica root, motherwort, astragalus root, ginseng or Codonopsis pilosula, any one of the compositions may also comprise baras camphor, rosewood oil, liquidambar orientalis mill, musk or musk ketone. The invention also discloses preparations using any one of the medicinal compositions as the effective constituents, preferably drop pills. The auxiliary materials of the drop pill substrate can be polyethylene glycol or natural materials, especially those of plant sources. The medicament has quick effect and good therapeutic action for coronary disease and angina pectoris.

The invention relates to a composition and a preparation process, a testing process and an application thereof. The composition comprises a therapeutically effective amount of candesartan or pharmaceutically acceptable ester or salt, a therapeutically effective amount of amlodipine or other pharmaceutically acceptable salt, 70-150 parts of mannitol or lactose, 2-5 parts of croscarmellose sodium or cross-calcium carboxymethyl cellulose and 5-40 parts of microcrystalline cellulose or corn starch. The composition is easy to prepare, low in production cost, utilizes accessories of unique prescription, and the like, can be prepared into oral preparation in forms of tablets, capsules, granules and the like by means of pharmaceutics, can be checked by different checking processes, has high quality, has functions of treating hypertension, angina pectoris and kidney diseases and has effect of myocardial protection.

The invention relates to extractive taking blattaria used as the medical source and being applied to the angiocarpy field, the preparation method thereof and a composition containing the extractive and pharmaceutically acceptable carrier. The extractive adopts water, alcohol and/or methanol as the extracting dissolvent, wherein, the volume concentration of the aqueous solution of the alcohol and/or methanol is 0 less than or equal to V/V less than or equal to 60 percent. The extractive has the advantages that blood fat is reduced, cholesterin is reduced, angina pectoris is prevented, the heart is tonified, and heart failure is resisted. The extraction process of the invention is simple and highly effective, the specialization is strong, and the obtained product has high effective component content. The extractive of the invention can be produced to be the composition containing the extractive and the pharmaceutically acceptable carrier.

The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided.